Latest Als (ASX:ALQ) News

ALS Limited confirms a fully franked ordinary dividend of 19.4 cents per share and announces the Dividend Reinvestment Plan price at $21.97 with no discount applied.

ALS Limited has announced a partially franked interim dividend of 19.4 cents per share, payable mid-December, alongside a dividend reinvestment plan priced at $21.97 per share with no discount.

ALS Limited has reported a robust first half for FY26, with revenue climbing 13.3% to $1.7 billion and underlying NPAT rising 17.2%, driven by strong organic growth across all business streams and strategic investments in digital innovation.

ALS Limited has posted a robust first half for FY26 with underlying EBIT growth of 14.7%, driven by strong performance in its Commodities segment and improved Life Sciences results. The company also raised its interim dividend and updated its growth outlook for the year.

ALS Limited has announced an ordinary dividend of AUD 0.194 per share for the half-year ending September 2025, accompanied by a fully franked 30% component and a Dividend Reinvestment Plan with no discount.

ALS Limited reported a robust half-year performance with underlying revenue up 13.3% and net profit after tax rising 17.2%, driven by strong growth in both Commodities and Life Sciences divisions. The company also declared a higher interim dividend and advanced its global expansion strategy.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

ALS Limited reported a robust FY25 with 16% revenue growth to AUD 3 billion, underpinned by strong organic expansion and key acquisitions. Despite slight NPAT decline, the company advances its sustainability agenda and invests in global lab upgrades.

ALS Limited has launched a Share Purchase Plan allowing eligible shareholders to invest up to A$30,000 in new shares at a discounted price, following a recent $350 million institutional placement.

ALS Limited has completed a significant institutional placement, issuing over 20.9 million shares at A$16.70 each, bolstering its capital base without the need for full disclosure under the Corporations Act.

ALS Limited has successfully completed a $350 million institutional placement, issuing 21 million new shares to fund key laboratory upgrades and maintain financial flexibility. The company also launched a $40 million share purchase plan to further support its growth ambitions.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.